The primary aim of this french multicenter national study is to assess and compare time to quality of life score deterioration (targeted dimensions : global health, fatigue and emotional functionning of EORTC QLQC30 according to the first line chemotherapy associated with bevacizumab in metastatic colorectal patients.
Study Type
OBSERVATIONAL
Enrollment
320
CHRU Besançon
Besançon, Franche Comté, France
RECRUITINGtime to health related quality of life score deterioration (targeted dimensions of EORTC QLQC30 : global health, fatigue, emotional functioning)
The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients.
Time frame: 1 year
time to health related quality of life score deterioration (non targeted dimensions of EORTC QLQC30 and CR 29)
Time frame: 1 year
INT PATSAT32
The EORTC IN-PATSAT32 is a 32-item satisfaction with care questionnaire to measure patients' appraisal of hospital doctors and nurses, as well as aspects of care organisation and services. It addresses technical competence, information provision, interpersonal skills, availability, waiting time, access, comfort and overall care perception
Time frame: 1 year
quality-adjusted life years (QALYs) using EQ5D
Time frame: 1 year
Overall survival
Time frame: 2 years
Progression Free Survival
Time frame: 1 year
treatment preference
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.